Michelle B Rokni1, Kelli B Pointer1, Jonathan George1, Jason J Luke2, Steven J Chmura1, Gage Redler3. 1. Department of Radiation and Cellular Oncology, The University of Chicago Medicine, Chicago, IL, USA. 2. Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh and UPMC Hillman Cancer Center, Pittsburgh, PA, USA. 3. Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Abstract
PURPOSE: Immune checkpoint inhibitors improve survival in metastatic diseases for some cancers. Multisite SBRT with pembrolizumab (SBRT + Pembro) was shown to be safe with promising local control using biologically effective doses (BEDs) = 95-120 Gy. Increased BED may improve response rate; however, SBRT doses are limited by surrounding organs at risk (OARs). The purpose of this work was to develop and validate methods for safe delivery of ultra-high doses of radiation (BED10 > 300) to be used in future clinical trials. METHODS AND MATERIALS: The radiation plans from 15 patients enrolled on a phase I trial of SBRT + pembro were reanalyzed. Metastatic disease sites included liver (8/15), inguinal region (1/15), pelvis (2/15), lung (1/15), abdomen (1/15), spleen (1/15), and groin (1/15). Gross tumor volumes (GTVs) ranged from 80 to 708 cc. Following the same methodology used in the Phase I trial on which these patients were treated, GTVs > 65 cc were contracted to a 65 cc subvolume (SubGTV) resulting in only a portion of the GTV receiving prescription dose. Volumetric modulated arc therapy (VMAT) was used to plan treatments BED10 = 360 Gy. Plans utilizing both 6FFF and 10FFF beams were compared to clinical plans delivering BED10 = 112.50 Gy. The target primary goal was V100% > 95% with a secondary goal of V70% > 99% and OAR objectives per the trial. To demonstrate feasibility, plans were delivered to a diode array phantom and evaluated for fidelity using gamma analysis. RESULTS: All 30 plans met the secondary coverage goal and satisfied all OAR constraints. The primary goal was achieved in 12/15 of the 6FFF plans and 13/15 of the 10FFF plans. Average gamma analysis passing rate using criteria of 3% dose difference and 3, 2, and 1 mm were 99.1 ± 1.0%, 98.5 ± 1.6%, and 95.1 ± 3.8%, respectively. CONCLUSION: Novel VMAT planning approaches with clinical treatment planning software and linear accelerators prove capable of delivering radiation doses in excess of 360 Gy BED10 to tumor subvolumes, while maintaining safe OAR doses.
PURPOSE: Immune checkpoint inhibitors improve survival in metastatic diseases for some cancers. Multisite SBRT with pembrolizumab (SBRT + Pembro) was shown to be safe with promising local control using biologically effective doses (BEDs) = 95-120 Gy. Increased BED may improve response rate; however, SBRT doses are limited by surrounding organs at risk (OARs). The purpose of this work was to develop and validate methods for safe delivery of ultra-high doses of radiation (BED10 > 300) to be used in future clinical trials. METHODS AND MATERIALS: The radiation plans from 15 patients enrolled on a phase I trial of SBRT + pembro were reanalyzed. Metastatic disease sites included liver (8/15), inguinal region (1/15), pelvis (2/15), lung (1/15), abdomen (1/15), spleen (1/15), and groin (1/15). Gross tumor volumes (GTVs) ranged from 80 to 708 cc. Following the same methodology used in the Phase I trial on which these patients were treated, GTVs > 65 cc were contracted to a 65 cc subvolume (SubGTV) resulting in only a portion of the GTV receiving prescription dose. Volumetric modulated arc therapy (VMAT) was used to plan treatments BED10 = 360 Gy. Plans utilizing both 6FFF and 10FFF beams were compared to clinical plans delivering BED10 = 112.50 Gy. The target primary goal was V100% > 95% with a secondary goal of V70% > 99% and OAR objectives per the trial. To demonstrate feasibility, plans were delivered to a diode array phantom and evaluated for fidelity using gamma analysis. RESULTS: All 30 plans met the secondary coverage goal and satisfied all OAR constraints. The primary goal was achieved in 12/15 of the 6FFF plans and 13/15 of the 10FFF plans. Average gamma analysis passing rate using criteria of 3% dose difference and 3, 2, and 1 mm were 99.1 ± 1.0%, 98.5 ± 1.6%, and 95.1 ± 3.8%, respectively. CONCLUSION: Novel VMAT planning approaches with clinical treatment planning software and linear accelerators prove capable of delivering radiation doses in excess of 360 Gy BED10 to tumor subvolumes, while maintaining safe OAR doses.
Authors: Gregory M Videtic; Rebecca Paulus; Anurag K Singh; Joe Y Chang; William Parker; Kenneth R Olivier; Robert D Timmerman; Ritsuko R Komaki; James J Urbanic; Kevin L Stephans; Sue S Yom; Clifford G Robinson; Chandra P Belani; Puneeth Iyengar; Munther I Ajlouni; Darindra D Gopaul; Jorge B Gomez Suescun; Ronald C McGarry; Hak Choy; Jeffrey D Bradley Journal: Int J Radiat Oncol Biol Phys Date: 2018-12-01 Impact factor: 7.038
Authors: Akila N Viswanathan; Sushil Beriwal; Jennifer F De Los Santos; D Jeffrey Demanes; David Gaffney; Jorgen Hansen; Ellen Jones; Christian Kirisits; Bruce Thomadsen; Beth Erickson Journal: Brachytherapy Date: 2012 Jan-Feb Impact factor: 2.362
Authors: Mitchell Machtay; Kyounghwa Bae; Benjamin Movsas; Rebecca Paulus; Elizabeth M Gore; Ritsuko Komaki; Kathy Albain; William T Sause; Walter J Curran Journal: Int J Radiat Oncol Biol Phys Date: 2010-10-25 Impact factor: 7.038
Authors: Thomas B Brunner; Oliver Blanck; Victor Lewitzki; Nasrin Abbasi-Senger; Felix Momm; Oliver Riesterer; Marciana Nona Duma; Stefan Wachter; Wolfgang Baus; Sabine Gerum; Matthias Guckenberger; Eleni Gkika Journal: Radiother Oncol Date: 2018-12-20 Impact factor: 6.280
Authors: James W Welsh; Chad Tang; Patricia de Groot; Aung Naing; Kenneth R Hess; John V Heymach; Vassiliki A Papadimitrakopoulou; Taylor R Cushman; Vivek Subbiah; Joe Y Chang; George R Simon; Rishab Ramapriyan; Hampartsoum B Barsoumian; Hari Menon; Maria Angelica Cortez; Erminia Massarelli; Quynh Nguyen; Padmanee Sharma; James P Allison; Adi Diab; Vivek Verma; Uma Raju; Sherif G Shaaban; Ramona Dadu; Maria E Cabanillas; Kelvin Wang; Clark Anderson; Daniel R Gomez; Stephen Hahn; Ritsuko Komaki; David S Hong Journal: Cancer Immunol Res Date: 2019-10-28 Impact factor: 11.151
Authors: S Corradini; F Alongi; N Andratschke; C Belka; L Boldrini; F Cellini; J Debus; M Guckenberger; J Hörner-Rieber; F J Lagerwaard; R Mazzola; M A Palacios; M E P Philippens; C P J Raaijmakers; C H J Terhaard; V Valentini; M Niyazi Journal: Radiat Oncol Date: 2019-06-03 Impact factor: 3.481